Jinni Wang on Muck Rack

Jinni Wang

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jinni

Contact Jinni, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial

|
By Qihua Zou, Shenrui Bai, Liang Wang, Hongyan Tong, Dongfeng Zeng, Ying Zhao, Yuerong Shuang, Xiaobo Wang, Xiuhua Sun, Zhenya Hong, Zhigang Peng, Yu Yang, Runhui Zheng, Huiqiang Huang, Jianbo Liu, Chunmei Yang, Xin Gao, Hao Xu, Daoguang Chen, Xiaojie Fang, Man Nie, Jinni Wang, Xinna Gao, Jingjing Ye, Wei Zhang, Jianzhen Shen, Rong Tao, Hong Cen, Yuchen Zhang, Jun Cai, Yi Xia, Qingqing Cai
| Nature Verified
Abstract Treatment options for relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) remain limited. In this phase 1b/2 trial (NCT05464433), we evaluated the safety and efficacy of liposomal mitoxantrone (Lipo-MIT) plus anti-PD-1 tislelizumab in this setting. During dose escalation, patients received Lipo-MIT (16 or 20 mg/m2) plus tislelizumab using a 3 + 3 design, followed by dose expansion at the recommended phase 2 dose (RP2D).
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified